1. Home
  2. ROK vs ARGX Comparison

ROK vs ARGX Comparison

Compare ROK & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ROK
  • ARGX
  • Stock Information
  • Founded
  • ROK 1903
  • ARGX 2008
  • Country
  • ROK United States
  • ARGX Netherlands
  • Employees
  • ROK N/A
  • ARGX N/A
  • Industry
  • ROK Industrial Machinery/Components
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ROK Industrials
  • ARGX Health Care
  • Exchange
  • ROK Nasdaq
  • ARGX Nasdaq
  • Market Cap
  • ROK 38.5B
  • ARGX 39.6B
  • IPO Year
  • ROK 1987
  • ARGX 2017
  • Fundamental
  • Price
  • ROK $350.06
  • ARGX $668.54
  • Analyst Decision
  • ROK Buy
  • ARGX Strong Buy
  • Analyst Count
  • ROK 16
  • ARGX 17
  • Target Price
  • ROK $342.31
  • ARGX $746.94
  • AVG Volume (30 Days)
  • ROK 1.1M
  • ARGX 446.0K
  • Earning Date
  • ROK 08-06-2025
  • ARGX 07-31-2025
  • Dividend Yield
  • ROK 1.54%
  • ARGX N/A
  • EPS Growth
  • ROK N/A
  • ARGX N/A
  • EPS
  • ROK 8.52
  • ARGX 18.75
  • Revenue
  • ROK $8,061,200,000.00
  • ARGX $3,120,821,000.00
  • Revenue This Year
  • ROK N/A
  • ARGX $64.75
  • Revenue Next Year
  • ROK $6.76
  • ARGX $29.81
  • P/E Ratio
  • ROK $39.83
  • ARGX $31.97
  • Revenue Growth
  • ROK N/A
  • ARGX 88.04
  • 52 Week Low
  • ROK $215.00
  • ARGX $510.06
  • 52 Week High
  • ROK $360.92
  • ARGX $696.21
  • Technical
  • Relative Strength Index (RSI)
  • ROK 50.47
  • ARGX 65.66
  • Support Level
  • ROK $337.16
  • ARGX $650.01
  • Resistance Level
  • ROK $347.17
  • ARGX $670.71
  • Average True Range (ATR)
  • ROK 8.09
  • ARGX 11.79
  • MACD
  • ROK -0.57
  • ARGX -1.86
  • Stochastic Oscillator
  • ROK 80.93
  • ARGX 54.32

About ROK Rockwell Automation Inc.

With roots tracing back to the early 1900s, Rockwell Automation is the successor to Rockwell International, which spun off its avionics segment in 2001. It is a pure-play industrial automation company that operates through three segments. Its largest segment by revenue, intelligent devices, sells factory floor-level devices such as motors, drives, sensors, relays, and actuators. Its software and control segment sells visualization, simulation, and human-machine interface software and control products such as programmable controllers, computers, and operator terminals. Its smallest segment, lifecycle services, offers digital consulting, engineered-to-order services, and other outsourced services such as remote monitoring, cybersecurity, and asset and plant maintenance and optimization.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: